All Insights


Spring Budget 2023 | What tax measures were announced?

A budget for growth but no cuts in tax rates
Life Sciences and Healthcare

Spring Budget 2023 | UK chancellor announces new regulatory model for medicines and medical technologies

Move raises the question of whether regulatory framework for medicines and medical devices will diverge from the EU model in
Regulatory and compliance

Consultation opens on proposed revisions to the Veterinary Medicines Regulations in Great Britain

Businesses involved in the manufacture, distribution and dispensation of veterinary medicinal products should take the opportunity to respond before the
Regulatory Outlook

Products | UK Regulatory Outlook February 2023

Medical Technology Strategy | UK to introduce regulatory framework for point of care manufacturing | Commission launches call for evidence
Regulatory and compliance

UK NHS suppliers required to commit to net zero by 2050 or lose out on future contract opportunities

From April, bidders for NHS contracts over £5 million must produce a carbon reduction plan

Enforcement risks mount in Germany for comparison and intermediary platforms

German watchdog is pursuing misleading behaviour and lack of transparency on ranking, reviews and market coverage
Life Sciences and Healthcare

Telemedicine in Italy takes next step following pandemic regulatory advance

The 'care relationship' between the physician and the patient will be transformed by telemedicine if not superseded

2023 predictions: What's on the horizon for US businesses operating in Europe?

By staying ahead of the curve and preparing for changes, US businesses can remain competitive and successful in Europe
Life Sciences and Healthcare

New year brings healthcare professional interaction rule update in Belgium

The new rules offer more flexibility to life sciences businesses interacting with health professionals and organisations
Life Sciences and Healthcare

Products without an intended medical purpose: EU clarifies conditions

Non-medical product manufacturers have limited time to prepare for new risk management and clinical data obligations
Life Sciences and Healthcare

The UK Patents Court puts an arrow through Teva's application for declaratory relief

Court of Appeal makes clear the limits on obtaining Arrow declaratory relief for deployment in other jurisdictions